Validating Large Language Models for Identifying Pathologic Complete Responses After Neoadjuvant Chemotherapy for Breast Cancer Using a Population-Based Pathologic Report Data

Author:

Cheligeer Cheligeer1,Wu Guosong1,Laws Alison2,Quan May Lynn3,Li Andrea1,Brisson Anne-Marie3,Xie Jason1,Xu Yuan3

Affiliation:

1. Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Calgary

2. Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary

3. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary

Abstract

Abstract In the context of breast cancer management, the accurate determination of pathologic complete response (pCR) from large narrative pathology reports is pivotal for cancer outcome and survivorship studies. Leveraging the Large Language Models (LLMs) in digital pathology, our study developed and validated methods for identifying pCR from pathology reports of 351 breast cancer patients who underwent neoadjuvant chemotherapy. The optimum method demonstrated a sensitivity of 100.0% (95%CI: 100.0-100.0%), positive predictive value of 84.0% (95%CI: 70.0-96.8%), and F1 score of 91.3% (95%CI: 81.5–98.1%). These algorithms, integrating diverse LLMs, exhibited superior performance compared to traditional machine learning models. Our findings suggest LLMs hold significant potential utility in clinical pathology for extracting critical information from textual data.

Publisher

Research Square Platform LLC

Reference32 articles.

1. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer. Use as an Endpoint to Support Accelerated Approval Guidance for Industry. Food and Drug Administration; 2020.

2. Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer;Mamounas EP;Ann Surg Oncol,2015

3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar P;Lancet,2014

4. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer;Korn E;Ann Oncol,2016

5. Electronic health records-driven phenotyping: challenges, recent advances, and perspectives;Pathak J;J Am Med Inf Assn,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3